Association between metabolic syndrome and the risk of Parkinson's disease: a meta-analysis.

IF 2.2 3区医学 Q3 CLINICAL NEUROLOGY

BMC Neurology Pub Date : 2024-09-04 DOI:10.1186/s12883-024-03820-y

Yuan Zhong, Tian-Hong Wang, Li-Jiang Huang, Yu-Si Hua

{"title":"Association between metabolic syndrome and the risk of Parkinson's disease: a meta-analysis.","authors":"Yuan Zhong, Tian-Hong Wang, Li-Jiang Huang, Yu-Si Hua","doi":"10.1186/s12883-024-03820-y","DOIUrl":null,"url":null,"abstract":"Background: There is still a lack of knowledge about the relationship between metabolic syndrome (MetS) and Parkinson's disease (PD). This study aimed to determine whether MetS increases PD risk.Methods: To identify relevant clinical studies, databases such as PubMed, Embase, and the Cochrane Library were searched in depth from the inception of databases until March 31, 2024. The study evaluated the correlation between MetS and the likelihood of developing PD through the computation of aggregated relative risks (RR) and their respective 95% confidence intervals (CIs) utilizing selnRR and lnRR.Results: Seven studies were included in our systematic review. The meta-analysis revealed that patients with MetS have a 0.3-fold increased risk of developing PD (p = 0.001). Furthermore, the analysis revealed a positive correlation between central obesity and the incidence of PD, with an RR of 1.19 (95% CI, 1.16-1.22; p = 0.001), as well as a greater risk of PD in patients with elevated blood pressure, with an RR of 1.13 (95% CI, 1.07-1.19; p = 0.001); elevated serum triglyceride levels, with an RR of 1.09 (95% CI, 1.02-1.15; p = 0.001); lower serum HDL cholesterol levels, with an RR of 1.21 (95% CI, 1.15-1.28; p = 0.001); and elevated plasma fasting glucose levels, with an RR of 1.18 (95% CI, 1.11-1.26; p = 0.001).Conclusion: MetS can contribute to the incidence of Parkinson's disease, with individual components of MetS demonstrating comparable effects.","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373127/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12883-024-03820-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is still a lack of knowledge about the relationship between metabolic syndrome (MetS) and Parkinson's disease (PD). This study aimed to determine whether MetS increases PD risk.

Methods: To identify relevant clinical studies, databases such as PubMed, Embase, and the Cochrane Library were searched in depth from the inception of databases until March 31, 2024. The study evaluated the correlation between MetS and the likelihood of developing PD through the computation of aggregated relative risks (RR) and their respective 95% confidence intervals (CIs) utilizing selnRR and lnRR.

Results: Seven studies were included in our systematic review. The meta-analysis revealed that patients with MetS have a 0.3-fold increased risk of developing PD (p = 0.001). Furthermore, the analysis revealed a positive correlation between central obesity and the incidence of PD, with an RR of 1.19 (95% CI, 1.16-1.22; p = 0.001), as well as a greater risk of PD in patients with elevated blood pressure, with an RR of 1.13 (95% CI, 1.07-1.19; p = 0.001); elevated serum triglyceride levels, with an RR of 1.09 (95% CI, 1.02-1.15; p = 0.001); lower serum HDL cholesterol levels, with an RR of 1.21 (95% CI, 1.15-1.28; p = 0.001); and elevated plasma fasting glucose levels, with an RR of 1.18 (95% CI, 1.11-1.26; p = 0.001).

Conclusion: MetS can contribute to the incidence of Parkinson's disease, with individual components of MetS demonstrating comparable effects.

查看原文本刊更多论文

代谢综合征与帕金森病风险之间的关系：一项荟萃分析。

背景：人们对代谢综合征（MetS）与帕金森病（PD）之间的关系仍然缺乏了解。本研究旨在确定代谢综合征是否会增加帕金森病的风险：为了确定相关的临床研究，我们对 PubMed、Embase 和 Cochrane Library 等数据库进行了深入检索，检索时间从数据库建立之初到 2024 年 3 月 31 日。研究通过利用selnRR和lnRR计算总相对风险（RR）及其各自的95%置信区间（CI），评估了MetS与罹患PD可能性之间的相关性：我们的系统综述纳入了七项研究。荟萃分析显示，MetS 患者罹患帕金森病的风险增加了 0.3 倍（p = 0.001）。此外，分析还显示，中心性肥胖与髓鞘性白内障发病率呈正相关，RR 为 1.19 (95% CI, 1.16-1.22; p = 0.001)，血压升高的患者罹患髓鞘性白内障的风险更大，RR 为 1.13 (95% CI, 1.07-1.19; p = 0.001）；血清甘油三酯水平升高，RR为1.09（95% CI，1.02-1.15；P = 0.001）；血清高密度脂蛋白胆固醇水平降低，RR为1.21（95% CI，1.15-1.28；P = 0.001）；血浆空腹血糖水平升高，RR为1.18（95% CI，1.11-1.26；P = 0.001）：结论：MetS可导致帕金森病的发病率，MetS的各个组成部分可产生类似的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Neurology 医学-临床神经学

CiteScore

4.20

自引率

0.00%

发文量

428

审稿时长

3-8 weeks

期刊介绍： BMC Neurology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.

文献相关原料

公司名称	产品信息	采购帮参考价格